This continuing education (CE) activity has been designed to meet the educational needs of Women’s Health Nurse Practitioners, Adult Nurse Practitioners, Family Nurse Practitioners, Certified Nurse Midwives involved in women’s health.
• CE Approval Period: Now until August 31, 2016
• Estimated Time to Complete This Activity: 1 hour
More than one-third (or 78.6 million) of adults in the United States are obese. Obesity prevalence varies across the country with the greatest numbers of obese individuals reported in the South followed by the Midwest, Northeast, and West. As of 2013, no state had a prevalence of obesity lower than 20%. Models forecast that 42% to 51% of the U.S. population will be obese by 2030. Obesity is associated with an increased risk for several comorbidities, including coronary heart disease, high blood pressure, stroke, type 2 diabetes, abnormal blood fats, metabolic syndrome, cancer, osteoarthritis, sleep apnea, obesity hypoventilation syndrome, and gallstones. In women, obesity also contributes to reproductive health issues, including fertility, pregnancy and fetal health, and issues with contraception. The high number of overweight and obese individuals along with the elevated risk for comorbid diseases carries a significant economic burden. It has been reported that compared with normal-weight individuals, obese patients in the U.S. incurred 46% increased inpatient costs, 27% more physician visit and outpatient costs, and 80% increased spending on prescription drugs. The annual extra medical costs of obesity in the U.S. were estimated at $75 billion in 2003 and accounted for 4% to 7% of total healthcare expenditures. In 2008, the medical care costs of obesity exceeded $147 billion.
Research has demonstrated that weight loss in obese men and women leads to a reduction in the risks and side effects of chronic medical conditions, as well as restores fertility and decreases complications during pregnancy, childbirth, and postnatal care in women. It has also been shown that a weight loss of only 5% to 10% of a person’s total body weight can lead to an increase in health benefits. Primary care clinics are the ideal setting for the early identification and management of obesity; however, data indicate a lack of appropriate understanding and adequate competence regarding obesity. Given the elevated health burden for obese men and women and the significant reduction in complications when weight loss occurs, it is imperative that clinicians who are likely to first encounter obese patients, such as nurse practitioners (NPs), initiate and implement weight-loss and weight-maintenance treatment plans, and are aware of the current recommended management guidelines and therapeutics for obese patients.
- At the conclusion of this educational activity, participants should be able to:
- Apply communication strategies to initiate and implement weight management programs for overweight and obese female patients
- Employ recommendations from the ACC/AHA/TOS/NHLBI and ANPF weight management guidelines to individualize weight loss treatment plans for overweight and obese female patients
- Evaluate the safety and efficacy of current and emerging pharmacotherapies for obesity
- Individualize weight loss maintenance programs for overweight and obese female patients based on patient factors
This activity has been evaluated and approved by the Continuing Education Approval Program of the National Association of Nurse Practitioners in Women’s Health (NPWH), and has been approved for 1 contact hour of CE credit, including 1 contact hour of pharmacology content.
Activity Number J-15-08
NPWH policy requires all faculty to disclose any affiliation or relationship with a commercial interest that may cause a potential, real, or apparent conflict of interest with the content of a CE program. NPWH does not imply that the affiliation or relationship will affect the content of the CE program. Disclosure provides participants with information that may be important to their evaluation of an activity. Faculty are also asked to identify any unlabeled/unapproved uses of drugs or devices made in their presentation.
W. Timothy Garvey, MD
Speaker’s Bureau: Merck Consultant/Advisory Board: Boehringer Ingelheim; Eisai Inc; Janssen Pharmaceuticals, Inc; LipoScience, Inc; Novo Nordisk; Takeda Pharmaceuticals International, Inc; Vivus, Inc, Investigator (contracted research, grants, etc): AstraZeneca; Eisai Inc; Merck; Sanofi US; Vivus, Inc; Weight Watchers International, Inc Ownership Interests: Bristol-Myers Squibb; Eli Lilly and Company; Merck; Novartis; Pfizer Inc; He will present off-label (non‒FDA-approved) use of liraglutide.
Mary Annette Hess, PhD, CRNP, FNP-BC
Dr. Hess reports she has no conflicts of interest. She does not intend to present information related to any non‒FDA-approved or investigational use of any product/device
Disclosure of Unlabeled Use:
NPWH policy requires authors to disclose to participants when they are presenting information about unlabeled use of a commercial product or device or an investigational use of a drug or device not yet approved for any use.
Participating faculty members determine the editorial content of CE activity; this content does not necessarily represent the views of NPWH or Takeda Pharmaceuticals International, Inc., US Region and Orexigen Therapeutics, Inc. This content has undergone a blinded peer review process for validation of clinical content. Although every effort has been made to ensure that the information is accurate, clinicians are responsible for evaluating this information in relation to generally accepted standards in their own communities and integrating the information in this activity with that of established recommendations of other authorities, national guidelines, FDA-approved package inserts, and individual patient characteristics.
This activity supported by an unrestricted educational grant from Takeda Pharmaceuticals International, Inc, US Region and Orexigen Therapeutics, Inc. to NPWH.